Biomunex announces the upcoming start of clinical development  of IPN60330, the first MAIT engager, a new therapeutic class in  oncology, following the completion of the FDA review period 

Biomunex announces strategic Artificial Intelligence collaborations to further accelerate the discovery and development processes of its innovative pipeline of cancer immunotherapies 

Biomunex Pharmaceuticals will showcase its MAIT Engager Platform during the 11th Annual Oncology Innovation Forum in San Francisco

Biomunex to Present Preclinical Data of its MAIT Engager Platform in Immuno-Oncology at 2025 SITC Annual Meeting

Biomunex announces investment from new shareholders to accelerate its growth and development of its portfolio of innovative bispecific antibodies for cancer immunotherapy

Biomunex Pharmaceuticals appoints its new Scientific Advisory Board on MAIT, composed of MAIT cells experts to accelerate the development of its MAIT engagers in immuno-oncology

Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

Biomunex Pharmaceuticals, a company specialized in cancer therapeutics, presents new preclinical data on its proprietary MAIT cell redirection approach at the AACR 2024

Biomunex signs exclusive licensing agreement with Institut Curie to develop MAIT engagers, a new class of bispecific antibodies in immuno-oncology 

Biomunex Pharmaceuticals announces the start of a Phase 1 clinical trial for its first-in-class bispecific antibody for the treatment of cancer

Biomunex is nominated for the Prix Galien USA in the “Best Startup” category, further recognizing the innovative nature of its bi- and multi-specific antibody technologies in immunotherapy of cancer

Biomunex Pharmaceuticals signs strategic license and co-development agreement with Onward Therapeutics for proprietary bispecific antibody program

Biomunex Pharmaceuticals signs a licensing agreement with Sanofi for the development of bi and multi-specific antibodies